

2016 NCCN Nursing Program Addresses Information Needs for Oncology Nurses

On March 30, 2016, NCCN hosted its 2016 Nursing Program: Advancing Oncology Nursing in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care at The Diplomat in Hollywood, Florida. Covering a broad range of topics from supportive care to disease-specific clinical advances to global outreach, this 1-day program provides oncology nurses with comprehensive and clinically relevant information regarding the management of people with cancer.

The day commenced with a presentation on the management of cardiac toxicities from Anecita Fadol, PhD, RN, FNP-BC, FAANP, The University of Texas MD Anderson Cancer Center. Dr. Fadol explained approaches for identifying causes of cardiac toxicity in people with cancer and discussed how cardiomyopathy can be prevented following anthracycline treatment. She also touched on the importance of encouraging healthy lifestyles in cancer survivors.

Kristen Kreamer, AOCNO, APRN-BC, CRNP, MSN, Fox Chase Cancer Center, provided a nutrition update, specifically focused on anorexia and cachexia. Ms. Kreamer described contributing causes of cancer cachexia, outlining the effects of anorexia and cachexia on outcomes in people with cancer and evaluating current and possible future treatment options.

This year's program featured concurrent clinical sessions from which attendees could choose the subject most pertinent to them. During the following presentations, experts from NCCN Member Institutions discussed evidence-based treatment updates and potential future therapies, as well as described processes for identifying and treating adverse events that accompany treatment:

- **Clinical Updates and Issues: Metastatic Breast Cancer**
Emily Olson, APRN, CNP, MSN, OCN, Mayo Clinic Cancer Center
- **Clinical Updates and Issues: T-Cell Lymphomas**
Susan McCall, ANP-BC, AOCNP, Memorial Sloan Kettering Cancer Center
- **Clinical Updates and Issues: Relapsed/Refractory Multiple Myeloma**
Beth Faiman, PhD, MSN, APRN-BC, AOCN, Cleveland Clinic Taussig Cancer Institute
- **Clinical Updates and Issues: Advanced Non-Small Cell Lung Cancer**
Tracy Ruegg, MSN, CNP, AOCN, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Brenda Shelton, DNP, RN, APRN-CNS, CCRN, AOCN, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, outlined both the recognition of signs of sepsis as well as treatment for the condition. Ms. Shelton also provided guidance on the proper documentation of sepsis for patients with cancer.

The day's final presentation, delivered by Lori Buswell, ANP-BC, MS, OCN, Dana-Farber Cancer Institute, focused on the need for global outreach efforts in oncology. Ms. Buswell discussed the importance of nurses in such efforts, highlighting the rewards and challenges associated.

The next NCCN Nursing Program is planned for the NCCN 22nd Annual Conference in Orlando, Florida, in 2017.

Live webinars for the NCCN 2016 Nursing Programs are available for those who were unable to attend the Conference. For more information, visit NCCN.org/events.

August 2016

2016 NCCN Fellows Recognition Program Explores New Horizons in Quality Cancer Care

On Sunday, April 3, 2016, the NCCN hosted more than 60 fellows during 2016 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care, which was held in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care at The Diplomat in Hollywood, Florida. This half-day program is dedicated to providing fellows from leading US cancer centers with the opportunity to hear from world-class specialists about the latest treatment advances in particular disease sites.

The program commenced with a discussion around advances in the management of relapsed/refractory multiple myeloma and Waldenström's Macroglobulinemia. Steven P. Treon, MD, PhD, Dana-Farber/Brigham and Women's Cancer Center compared current treatments and summarized emerging data with novel agents and combination regimens for the diseases.

Following Dr. Treon, Robert J. Morgan, MD, City of Hope Comprehensive Cancer Center, explored recurrence therapy for ovarian cancer, outlining specific categories of recurrence therapies for ovarian cancer and assessed recent recommendations for such therapies in patients, including appropriate dose selection, sequencing, adverse event management, and when to cease therapy.

During their presentation on surgical approaches to systemic therapies in the management of kidney cancer, Steven L. Chang, MD, MS, and Toni K. Choueiri, MD, Dana-Farber/Brigham and Women's Cancer Center, summarized the benefits and risks of current surgical and systemic treatment options and evaluated the promising immunotherapy approaches currently being studied in clinical trials.

Billy W. Loo Jr, MD, PhD, Stanford Cancer Institute, followed with a presentation on recent advances in radiation therapy for non-small cell lung cancer, including stereotactic ablative radiotherapy in early-stage lung cancer and highly conformal radiation therapy in locally advanced lung cancer.

During the day's final presentation, Al B. Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Douglas W. Blayney, MD, Stanford Cancer Institute, discussed the variances between careers at academic centers versus community hospitals. Dr. Benson and Dr. Blayney touched on important considerations for the fellows in attendance, including but not limited to determination of personal priorities, definitions of career success, desire to teach, and salary.

NCCN plans to hold the next NCCN Fellows Recognition Program during the NCCN 22nd Annual Conference in 2017 in Orlando, Florida.

2016 NCCN Fellows Recognition Program Explores New Horizons in Quality Cancer Care

On Sunday, April 3, 2016, the NCCN hosted more than 60 fellows during 2016 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care, which was held in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care at The Diplomat in Hollywood, Florida. This half-day program is dedicated to providing fellows from leading US cancer centers with the opportunity to hear from world-class specialists about the latest treatment advances in particular disease sites.

The program commenced with a discussion around advances in the management of relapsed/refractory multiple myeloma and Waldenström's Macroglobulinemia. Steven P. Treon, MD, PhD, Dana-Farber/Brigham and Women's

Cont. on page xxxii.

August 2016

Cont. from page xxvii.

Cancer Center compared current treatments and summarized emerging data with novel agents and combination regimens for the diseases.

Following Dr. Treon, Robert J. Morgan, MD, City of Hope Comprehensive Cancer Center, explored recurrence therapy for ovarian cancer, outlining specific categories of recurrence therapies for ovarian cancer and assessed recent recommendations for such therapies in patients, including appropriate dose selection, sequencing, adverse event management, and when to cease therapy.

During their presentation on surgical approaches to systemic therapies in the management of kidney cancer, Steven L. Chang, MD, MS, and Toni K. Choueiri, MD, Dana-Farber/Brigham and Women's Cancer Center, summarized the benefits and risks of current surgical and systemic treatment options and evaluated the promising immunotherapy approaches currently being studied in clinical trials.

Billy W. Loo Jr, MD, PhD, Stanford Cancer Institute, followed with a presentation on recent advances in radiation therapy for non-small cell lung cancer, including stereotactic ablative radiotherapy in early-stage lung cancer and highly conformal radiation therapy in locally advanced lung cancer.

During the day's final presentation, Al B. Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Douglas W. Blayney, MD, Stanford Cancer Institute, discussed the variances between careers at academic centers versus community hospitals. Dr. Benson and Dr. Blayney touched on important considerations for the fellows in attendance, including but not limited to determination of personal priorities, definitions of career success, desire to teach, and salary.

NCCN plans to hold the next NCCN Fellows Recognition Program during the NCCN 22nd Annual Conference in 2017 in Orlando, Florida.

References

1. Myelodysplastic Syndromes (MDS). AAMDSIF Home. Available at: <http://www.aamds.org/diseases/mds>. Accessed June 20, 2016.

NCCN Accepted as CMS-Approved Provider-Led Entity for Development of Imaging Appropriate Use Criteria

NCCN, an alliance of 27 of the nation's leading cancer centers, has been recognized as a qualified provider-led entity (PLE) for the new Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS). Through this qualification, CMS—the nation's largest health payer—recognizes NCCN as a group qualified to develop AUC and establish policy and decision-making for diagnostic imaging in patients with cancer. NCCN Imaging AUC™ are available free of charge to registered users of NCCN.org and can be accessed at NCCN.org/ImagingAUC.

“NCCN is proud of this acknowledgement from CMS, and we congratulate our fellow PLEs on their recognition,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “At NCCN, we strive to improve the lives of people with cancer, and as a CMS-approved provider-led entity for development of diagnostic imaging AUC, we help to further assure that patients with cancer receive quality care while avoiding unnecessary diagnostic imaging.”

Adapted from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN Imaging AUC support clinical decision-making around the use of imaging in patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is committed to assuring

August 2016

that the most up-to-date recommendations are available and reviews and updates the NCCN Imaging AUC on a continual basis to ensure that the recommendations take into account the most current evidence.

Today, NCCN Imaging AUC for the following NCCN Guidelines are available:

- Acute Lymphoblastic Leukemia, Version 1.2016
- Acute Myeloid Leukemia, Version 1.2016
- Bladder Cancer, Version 2.2016
- Breast Cancer, Version 2.2016
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016
- Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016
- Hodgkin Lymphoma, Version 3.2016
- Lung Cancer Screening, Version 2.2016
- Neuroendocrine Tumors, Version 2.2016
- Pancreatic Adenocarcinoma, Version 1.2016
- Prostate Cancer, Version 3.2016
- Prostate Cancer Early Detection, Version 2.2016

NCCN Imaging AUC for additional cancer types will be published in the coming months.

NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. Since June 2008, CMS has recognized the NCCN Drugs & Biologics Compendium (NCCN Compendium) as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care.

For more information about NCCN Imaging AUC, visit NCCN.org/ImagingAUC.